☰

Pingping Mao, Ph.D. - Publications

Affiliations: 
2015 Experimental and Molecular Medicine Dartmouth College, Hanover, NH, United States 
Area:
Pharmacology
Tree Info Grants Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Gómez Tejeda Zañudo J, Mao P, Alcon C, Kowalski K, Johnson GN, Xu G, Baselga J, Scaltriti M, Letai A, Montero J, Albert R, Wagle N. Cell line-specific network models of ER+ breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations. Cancer Research. PMID 34257082 DOI: 10.1158/0008-5472.CAN-21-1208  0.349
2020 Mao P, Cohen O, Kowalski KJ, Kusiel J, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung JH, Freeman SS, Rozenblatt-Rosen O, Miller VA, Piccioni F, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32723837 DOI: 10.1158/1078-0432.Ccr-19-3958  0.38
2020 Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390  0.461
2020 Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09  0.526
2020 Wander S, Mao P, Lloyd M, Kowalski K, Johnson GN, Malvarosa G, Moy B, Ellisen LW, Iafrate J, Wagle N, Bardia A. Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-08  0.51
2020 Cohen O, Mao P, Nayar U, Buendia-Bue JE, Kim D, Jain E, Helvie K, Abravanel D, Kowalski KJ, Kapstad C, Freeman S, Adalsteinsson V, Wander SA, Waks AG, Getz G, et al. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-02  0.489
2019 Cohen O, Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock D, Leshchiner I, Dellostritto L, Garrido-Castro A, et al. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-02  0.301
2019 Zañudo JGT, Mao P, Montero J, Xu G, Kowalski KJ, Johnson GN, Baselga J, Scaltriti M, Letai AG, Wagle N, Albert R. Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-675  0.317
2019 Mao P, Cohen O, Kowalski K, Kusiel J, Buendia J, Exman P, Wander SA, Waks AG, Winer EP, Lin NU, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-314  0.371
2018 Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016  0.429
2018 Mao P, Kusiel J, Cohen O, Wagle N. Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd4-01  0.455
2017 Mao P, Quartey Q, Cohen O, Piccioni F, Wagle N. Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-08  0.474
2015 Chandran UR, Luthra S, Santana-Santos L, Mao P, Kim SH, Minata M, Li J, Benos PV, DeWang M, Hu B, Cheng SY, Nakano I, Sobol RW. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Genomics Data. 5: 333-336. PMID 26251826 DOI: 10.1016/J.Gdata.2015.07.007  0.349
2014 Yim CY, Mao P, Spinella MJ. Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives. The Aaps Journal. 16: 281-8. PMID 24431081 DOI: 10.1208/S12248-014-9562-2  0.623
2014 Mao P, Jardine MP, Rahme GJ, Yang EC, Tam J, Kodali A, Biswal B, Fadul CE, Gaur AB, Israel MA, Pletnev A, Spinella M. Abstract 4605: STK17A is a potential therapeutic target in glioblastoma Cancer Research. 74: 4605-4605. DOI: 10.1158/1538-7445.Am2014-4605  0.72
2013 Mao P, Hever-Jardine MP, Rahme GJ, Yang E, Tam J, Kodali A, Biswal B, Fadul CE, Gaur A, Israel MA, Spinella MJ. Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma. Plos One. 8: e81803. PMID 24312360 DOI: 10.1371/Journal.Pone.0081803  0.732
2012 Mao P, Jardine M, Niemaszyk L, Haghkerdar J, Yang E, yanco EG, Desai D, Beyrouthy M, Kerley-Hamilton JS, Freemantle SJ, Spinella MJ. Abstract 2958: The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner Cancer Research. 72: 2958-2958. DOI: 10.1158/1538-7445.Am2012-2958  0.66
2011 Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, Desai D, Beyrouthy MJ, Kerley-Hamilton JS, Freemantle SJ, Spinella MJ. Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells. The Journal of Biological Chemistry. 286: 19381-91. PMID 21489989 DOI: 10.1074/Jbc.M111.218040  0.651
Show low-probability matches.